<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00866684</url>
  </required_header>
  <id_info>
    <org_study_id>PROSKIN 01</org_study_id>
    <nct_id>NCT00866684</nct_id>
  </id_info>
  <brief_title>Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol</brief_title>
  <acronym>PROSKIN</acronym>
  <official_title>Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transplant recipients have a high risk to develop skin malignancies. This effect depends on
      the one hand on the immunosuppressive drugs themselves (i.e., azathioprine) and relates on
      the other hand on the dosage (i.e., calcineurin-inhibitors). Based on the encouraging results
      of previous, retrospective studies on patients treated with Sirolimus (SRL), these patients
      should be switched to an immunosuppressive regime including SRL, decreasing the dosage of
      calcineurin-inhibitors or converting from former immunosuppression. A conversion to a
      SRL-based therapy is effective in immunosuppression and safe regarding graft and patient
      survival.

      This study was designed to assess whether a switch to a SRL-immunosuppressive therapy
      decreases the incidence/reoccurrence of skin neoplasm.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient patient recruitment
  </why_stopped>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression of actinic keratosis I and II to III or invasive squamous cell carcinoma (SCC) or incidence/reoccurrence of neoplastic skin tumors</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient and graft survival rates, Incidence of non-cutaneous cancers and of selected AEs, Development of renal function, Renal biopsy changes, Development of proteinuria after conversation to SRL, Incidence and development of actinic keratosis I and II</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Kidney Transplantation</condition>
  <condition>Skin Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive Sirolimus in addition to their previous immunosuppressive therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will stay on their previous immunosuppressive regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Dosage form: coated tablet; Dosage: 4-8 micrograms/litre; Route of administration: oral use; Frequency: one tablet per day; Duration: 24 month</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Rapamune, ATC code: L04AA10</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azathioprine</intervention_name>
    <description>Dosage form: Coated tablet; dosage: 1-4 milligrams/kilogram; Frequency: daily; Duration: 24 month</description>
    <arm_group_label>2</arm_group_label>
    <other_name>ATC code: L04AX01</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate</intervention_name>
    <description>Dosage form: Tablet; dosage: 2 gram; Frequency: daily; Duration: 24 month</description>
    <arm_group_label>2</arm_group_label>
    <other_name>ATC code: L04AA06</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclosporin</intervention_name>
    <description>Dosage form: Capsule; Dosage: 50-80 micrograms/litre; Frequency: daily; Duration: 24 month</description>
    <arm_group_label>2</arm_group_label>
    <other_name>ATC code: L04AA01</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Dosage form: Capsule; dosage: 3-5 micrograms/litre; Frequency: daily; Duration: 24 month</description>
    <arm_group_label>2</arm_group_label>
    <other_name>ATC code: L04AA05</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recipients of renal allograft with current actinic keratosis I or II or successfully
             treated actinic keratosis III (inclusion possible immediately after completed wound
             healing from surgical excision), invasive squamous cell carcinoma (SCC), basal cell
             carcinoma and/or premalignant neoplastic skin lesions

          -  Age 18 years and older

          -  Minimum period of 6 month after renal transplantation

          -  Stable renal function and a calculated creatinine clearance of at least 40 ml/min

          -  Written informed consent

          -  Proteinuria ≤ 800 mg/d at time of enrolment

          -  Successfully treated solid tumor (no recurrence or metastasis in the last 2 years)

        Exclusion Criteria:

          -  Current Sirolimus- or Everolimus- intake

          -  Instable graft function (creatinine clearance &lt; 40 ml/min)

          -  Graft rejection within the 3 previous months

          -  Proteinuria &gt; 800 mg/d

          -  Non-controlled hyperlipidemia (Cholesterol &gt;7,8 mmol/l, Triglycerides &gt; 4)

          -  Leucopenia &lt; 2500/nl

          -  Thrombocytopenia &lt; 90/nl

          -  Pregnancy or breastfeeding

          -  Women of childbearing age without highly effective contraception (= defined as those
             which result in a low failure rate (i.e. less than 1 % per year))

          -  Known allergy to macrolides

          -  Current participation in other studies

          -  Refusal to sign informed consent form

          -  Neoplasm other than defined as inclusion criteria

          -  All contraindications to SRL (see package insert, appendix)

          -  Persons who are detained officially or legally to an official institute
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Petra Reinke, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen, Hautklinik</name>
      <address>
        <city>Erlangen</city>
        <state>Bavaria</state>
        <zip>91052</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen, Medizinische Klinik IV</name>
      <address>
        <city>Erlangen</city>
        <state>Bavaria</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der LMU München, Medizinische Poliklinik Innenstadt</name>
      <address>
        <city>München</city>
        <state>Bavaria</state>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der LMU München, Klinik und Poliklinik für Dermatologie</name>
      <address>
        <city>München</city>
        <state>Bavaria</state>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar, Klinik und Poliklinik für Dermatologie und Allergologie</name>
      <address>
        <city>München</city>
        <state>Bavaria</state>
        <zip>80802</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar, II. Medizinische Klinik und Poliklinik</name>
      <address>
        <city>München</city>
        <state>Bavaria</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Regensburg, Dermatologie</name>
      <address>
        <city>Regensburg</city>
        <state>Bavaria</state>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Regensburg, Nephrologie Innere Medizin II</name>
      <address>
        <city>Regensburg</city>
        <state>Bavaria</state>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken der Stadt Köln, Medizinische Klinik I</name>
      <address>
        <city>Köln</city>
        <state>North Rhine-Westphalia</state>
        <zip>51109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster, Klinik und Poliklinik für Hautkrankheiten</name>
      <address>
        <city>Münster</city>
        <state>North Rhine-Westphalia</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster, Med. Klinik und Poliklinik D</name>
      <address>
        <city>Münster</city>
        <state>North Rhine-Westphalia</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Wuppertal, Zentrum für Dermatologie, Allergologie und Umweltmedizin</name>
      <address>
        <city>Wuppertal</city>
        <state>North Rhine-Westphalia</state>
        <zip>42283</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, Klinik für Dermatologie, Venerologie und Allergologie</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, Klinik für Nieren- und Hochdruckkrankheiten</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin, Klinik für Dermatologie, Venerologie und Allergologie</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2009</study_first_submitted>
  <study_first_submitted_qc>March 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2009</study_first_posted>
  <last_update_submitted>September 1, 2015</last_update_submitted>
  <last_update_submitted_qc>September 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Petra Reinke</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>renal transplant-patients with high-risk for skin cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Immunosuppressive Agents</mesh_term>
    <mesh_term>Azathioprine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

